Clinical Trial
Study Details
Participants will receive anumigilimab, escalated to a maximum dose guided by absolute neutrophil count (ANC) and safety concerns.
Volume matched saline will be administered SC.
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD.
The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
Study Overview
Contacts and Locations
UAMS Medical Center
Little Rock, Arkansas 72202
United States
University of California Irvine
Orange, California 92868
United States
The Foundation for Sickle Cell Disease
Hollywood, Florida 33023-6703
United States
Arthur M. Blank Hospital- Children's Healthcare of Atlanta
Atlanta, Georgia 30329
United States
Center for Cancer and Blood Disorders
Bethesda, Maryland 20817
United States
Southern Specialty Research
Flowood, Mississippi 39232
United States
Jacobi Medical Center
The Bronx, New York 10461
United States
Ohio State University
Columbus, Ohio 43210
United States
Virginia Commonwealth University
Richmond, Virginia 23298
United States
CHU Saint-Pierre
1000 Brussels
Belgium
CHU de Nantes, Hotel-Dieu
44093 Nantes
France
Institut Universitaire du Cancer de Toulouse
31100 Toulou
France
AOUI Verona and University of Verona
37134 Verona
Italy
Central Middlesex Hospital
London
NW10 7NS
United Kingdom
St George's University Hopsitals NHS Foundation Trust
London
SW17 0QT
United Kingdom
Hammersmith Hospital Imperial College Healthcare NHS Trust
London
W120HS
United Kingdom